Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment

Lu, Xianfeng; Wang, Lixiang; Li, Guichen; Gao, Jianyuan; Wang, Ying

doi:10.1080/10717544.2021.1883158

Cited by 43 publications

(24 citation statements)

References 43 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability to specifically transport drugs to the pathological lesion of brain tissues of great importance for the treatment of CIS. Currently, there are two main approaches to facilitate drug passage through BBB for the treatment of CIS: (1) Nasal administration, after which, BBB can bypass the olfactory and trigeminal nerve pathways for direct transport into the brain [11,12], the way of which is convenient but still brings many problems, such as the low amount of polar macromolecular drugs into the brain (only 0.01% ~ 0.1% of the administered dose), easily affected absorption by pathological conditions such as cold and rhinitis as well as individual differences [13]; (2) Nanoparticle drug delivery systems for drug delivery, i.e., taking advantage of a variety of allosteric receptors and transporters on brain capillary endothelial cells, select their corresponding ligands as the target functional base, modify the surface of the drug delivery system, and mediate its trans-BBB transport into the brain [14,15]. This strategy can not only effectively overcome the barrier of BBB, but also increase the stability of the drug in the body and prolong its half-life in body system.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: A stepwise-targeting strategy for the treatment of cerebral ischemic stroke

Tan

Wang

et al. 2021

J Nanobiotechnol

View full text Add to dashboard Cite

Background Effective amelioration of neuronal damages in the case of cerebral ischemic stroke (CIS) is essential for the protection of brain tissues and their functional recovery. However, most drugs can not penetrate the blood–brain barrier (BBB), resulting in the poor therapeutic outcomes. Results In this study, the derivatization and dual targeted delivery technologies were used to actively transport antioxidant melatonin (MLT) into the mitochondria of oxidative stress-damaged cells in brain tissues. A mitochondrial targeting molecule triphenylphosphine (TPP) was conjugated to melatonin (TPP-MLT) to increase the distribution of melatonin in intracellular mitochondria with the push of mitochondrial transmembrane potential. Then, TPP-MLT was encapsulated in dual targeted micelles mediated by TGN peptide (TGNYKALHPHNG) with high affinity for BBB and SHp peptide (CLEVSRKNG) for the glutamate receptor of oxidative stress-damaged neural cells.TGN/SHp/TPP-MLT micelles could effectively scavenge the overproduced ROS to protect neuronal cells from oxidative stress injury during CIS occurrence, as reflected by the improved infarct volume and neurological deficit in CIS model animals. Conclusions These promising results showed this stepwise-targeting drug-loaded micelles potentially represent a significant advancement in the precise treatment of CIS. Graphical Abstract

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: A stepwise-targeting strategy for the treatment of cerebral ischemic stroke

Tan

Wang

et al. 2021

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…This knowledge is critical to the discovery of new chemical entities and/or repurposing of existing drugs for improvement of functional neurological outcomes following ischemic stroke. Indeed, several preclinical stroke studies have explored other technologies for CNS delivery of drugs including nanoparticles [32][33][34], liposomes [35,36], dendrimers [37], or therapeutic antibodies targeting the transferrin receptor for receptor-mediated transcytosis [38]. While these approaches have shown varying degrees of potential for clinical translation, they do not utilize putative membrane transporters that are functionally expressed at the BBB and, therefore, will not be discussed in this review.…”

Section: Introductionmentioning

confidence: 99%

Blood–Brain Barrier Transporters: Opportunities for Therapeutic Development in Ischemic Stroke

Nilles

Williams

Betterton

et al. 2022

IJMS

View full text Add to dashboard Cite

Globally, stroke is a leading cause of death and long-term disability. Over the past decades, several efforts have attempted to discover new drugs or repurpose existing therapeutics to promote post-stroke neurological recovery. Preclinical stroke studies have reported successes in identifying novel neuroprotective agents; however, none of these compounds have advanced beyond a phase III clinical trial. One reason for these failures is the lack of consideration of blood–brain barrier (BBB) transport mechanisms that can enable these drugs to achieve efficacious concentrations in ischemic brain tissue. Despite the knowledge that drugs with neuroprotective properties (i.e., statins, memantine, metformin) are substrates for endogenous BBB transporters, preclinical stroke research has not extensively studied the role of transporters in central nervous system (CNS) drug delivery. Here, we review current knowledge on specific BBB uptake transporters (i.e., organic anion transporting polypeptides (OATPs in humans; Oatps in rodents); organic cation transporters (OCTs in humans; Octs in rodents) that can be targeted for improved neuroprotective drug delivery. Additionally, we provide state-of-the-art perspectives on how transporter pharmacology can be integrated into preclinical stroke research. Specifically, we discuss the utility of in vivo stroke models to transporter studies and considerations (i.e., species selection, co-morbid conditions) that will optimize the translational success of stroke pharmacotherapeutic experiments.

show abstract

“…However, in the presence of normal saline solution, these positively charged nanoparticles have exhibited its direct attack on the cell membrane and cell wall in the term of plant which tends to destabilize it and in turn increases the production of reactive oxygen species being abbreviated as ROS. On the other hand in the same case, the cytotoxicity cannot be determined [41].…”

Section: ) Effect Of Surface Charge On the Biological Properties Of Nano Ceriamentioning

confidence: 99%

Use of Cerium Nitrate Nanoparticles in Biological Environment Along with the Factors Effecting It: An Empirical Overview

Fatima¹,

Quazi²,

Gavas³

et al. 2021

Preprint

View full text Add to dashboard Cite

The advancement in the production and usage of the cerium oxide nanoparticles have diverted the attention of scientists towards their usage in medical field and therapeutic usage. The clinical usage of these Nano ceria is based on their ability to moderate the oxidative stress and this is only because of their ability to change their valent state from +3 to +4 which makes them ideal for scavenging radicals for use in a number of systemic and neurodegenerative disorders. This review aims to synthesize the basic methods used for the synthesis of nanoparticles along with the use of ligand, stabilizing agent and other components. This review also concludes that how various physical and chemical properties of nanoparticles effect the basic biological activities such as antimicrobial activity, cytotoxicity and many others. However, during the standardization, some of the physiochemical properties, methods used for preparation and catalytic abilities must be taken into account.

show abstract

Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment

Abstract: (2021) Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment,

Cited by 43 publications

References 43 publications

RETRACTED ARTICLE: A stepwise-targeting strategy for the treatment of cerebral ischemic stroke

RETRACTED ARTICLE: A stepwise-targeting strategy for the treatment of cerebral ischemic stroke

Blood–Brain Barrier Transporters: Opportunities for Therapeutic Development in Ischemic Stroke

Use of Cerium Nitrate Nanoparticles in Biological Environment Along with the Factors Effecting It: An Empirical Overview

Contact Info

Product

Resources

About